<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0229239.ref023">
 <label>23</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Wyles</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Poordad</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Wang</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Alric</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Felizarta</surname>
   <given-names>F</given-names>
  </name>, 
  <name>
   <surname>Kwo</surname>
   <given-names>PY</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial</article-title>. 
  <source>Hepatol Baltim Md</source>. 
  <year>2017</year>
  <month>9</month>
  <day>19</day>;
 </mixed-citation>
</ref>
